

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/616,769

Filed:

07/10/2003

1st Inventor:

Y. MOMOSE

For:

Neurotrophin Production Promoting Agent

Atty. Dkt. No.

2630 US1P

Art Unit:

1614

Examiner:

tba

Allowed:

Batch:

Paper No.:

Supplemental Information Disclosure Statement

Commissioner for Patents P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached Form PTO-1449 previously submitted with a translation of the abstract. Applicants herewith provide English language translations of the entire documents identified in the previously submitted Information Disclosure Statement, as follows:

Reference Number A10	Document Author and Title Kawakita, T., et al. "Preparation of Benzoxazine Derivatives as Phospholipase A2 and Interleukin 1 Inhibitors" This reference will now be identified as JP 7242663 under "Foreign Patent Documents"
A11	Gieldanowsky, Jerzy, et al. "Pharmacological Activity in the Group of New Substitute Thiazoloacetic and Thiazinocarboxyl Acid Derivatives"
A13	Brown, Kevan, et al. "Nonsteroidal Antiinflammatory Agent. 1. 2,4-Diphenylthiazole-5-Acetic Acid and Related Compounds"
A16	Sharma, Pawan K., et al. "Synthesis and Antiinflammatory Activity of Some 1,4-Dihydro-3-Methyl-1-(2-Thiazolyl)Pyrazolo 4,3-c(1,1) Benzothiazine 5,5-Dioxides"
A17	Sawhney, S.N., et al. "Synthesis and Antiinflammatory Activity of Some 5-Thiazoleacetic Acids"
A19	Jacobiec, Tadeusz, et al. "Studies on the Derivatives of 2-Amino-4-P-Chlorophenylthiazole-5-Acetic Acid"
A20	Hirai, Kentaro, et al. "Synthesis of 2-Disubstituted-Amino-4-Arylthiazol-5-Ylalkanoic Acids"

Legible copies of said listed references are herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated:

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA 0 8 2004

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Action no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/616,769		
Filing Date	07/10/2003		
First Named Inventor	Y. MOMOSE		
Art Unit	1614		
Examiner Name	tba		
Attorney Docket Number	2630 US1P		

Examiner	Cite	Document Number	U. S. PATENT De	Name of Patentee or	Page Columns Lines Where
Initials*	No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
	l	1			
		US-			
		US-			
		US-			
· · · · · · · · · · · · · · · · · · ·		US-			
		US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
	 	US-			

			GN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	B1	JP 7-242663	09/19/1995	Yoshitomi Pharm		
	<u> </u>					
L					1	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

OIPE COR

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO & TRADE **Application Number** 10/616,769 INFORMATION DISCLOSURE **Filing Date** 07/10/2003 STATEMENT BY APPLICANT **First Named Inventor** Y. MOMOSE **Art Unit** 1614 (Use as many sheets as necessary) **Examiner Name** tba Attorney Docket Number Sheet 2 2630 US1P of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B2	Gieldanowski, Jerzy, et al. "Pharmacological Activity in the Group of New Substituted Thiazoloacetic and Thiazinocarboxyl Acid Derivatives" Archivum Immunologiae et Thereapiae Experiementalis 26:921-929 (1978)	~
	В3	Brown, Kevan, et al. "Nonsteroidal Antiinflammatory Agents. 1. 2,4-Diphenylthiazole-5-acetic Acid and Related Compounds" Journal of Medicinal Chemistry 17(11): 1177-1181(1974)	~
	B4	Sharma, Pawan K., et al. "Synthesis and Antiinflammatory Activity of Some 1,4-Dihydro-3-methyl-1-(2-thiazolyl)pyrazolo[4,3-c][1,2]benzothiazine 5,5-Diozides" Bull. Chem. Soc. Jpn. 66(12): 3843-3846 (1993)	V
	B5	Sawhney, S.N., et al. "Synthesis & Antiinflammatory Activity of Some 5-Thiazoleacetic Acids" Indian Journal of Chemistry 22B: 1044-1049(1983)	V
	В6	Jakobiec, Tadeusz, et al. "Studies on the Derivatives of 2-Amino-4-P-Chlorophenylthiazole-5-Acetic Acid" Archivum Immunologiae et Thereapiae Experiementalis, 27: 777-794 (1979)	~
	В7	Hirai, Kentaro, et al. "Synthesis of 2-Disubstituted-amino-4-arylthiazol-5-ylalkanoic Acids" Chem. Pharm. Bull. 25(9):2292-2299(1977)	V

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.